We analyzed this claim: is it true that
the US Food and Drug Administration granted accelerated approval to dostarlimab for adults with mismatch-repair-deficient locally advanced rectal cancer?
Regulatory filings confirm the agency granted early approval based on trial results showing tumors cleared without further therapy, while mandating a multiyear follow-up study.
US FDA clears rectal cancer immunotherapy
A newly authorized drug offers certain patients a chance to skip standard chemotherapy, radiation and organ-altering surgery.
The story continues
FDA approves GSK drug offering rare hepatitis B cure
22 October 2026Regulators cleared Hibsago as a 24-week injection that frees some patients from lifelong pills, but severe liver and platelet risks require weekly checks.
In a nutshell
US health regulators have approved the immunotherapy drug dostarlimab as an upfront treatment for rectal cancer patients whose tumors have specific DNA-repair defects, offering them a chance to clear their disease without standard surgery, chemotherapy or radiation. Early trial results showed that 71% of patients avoided additional treatment, but the approval is provisional: the drugmaker must track patients through 2030 to prove that organ preservation lasts and survival matches traditional surgery.
Highlights
- The US cleared dostarlimab for adults with locally advanced rectal cancer carrying MSI-H or dMMR genetic defects.
- In the AZUR-1 clinical trial, 71% of patients avoided surgery, chemotherapy and radiation after taking the drug.
- Independent review found 47% of evaluable trial patients had no detectable cancer for at least 12 months.
- Serious adverse reactions occurred in 20% of study participants, and six patient deaths were reported.
- Regulators require GSK to track patient survival and organ preservation through July 31, 2030.
From the Editor’s Diary
When a drug can replace major surgery, early regulatory access offers profound quality-of-life benefits, but confirming that the cancer stays gone requires years of patient monitoring.
Who's involved
US Food and Drug Administration (FDA)
The US government agency that decides which medicines are safe and effective for public use
goal → Grant earlier access to a promising cancer therapy while enforcing strict studies to verify its long-term benefits
GSK
The British drugmaker that manufactures and sells the immunotherapy drug Jemperli
goal → Secure new medical uses for the drug and demonstrate that avoiding surgery provides lasting health value
Memorial Sloan Kettering Cancer Center (MSK)
A major cancer research hospital in New York that led early studies testing the drug in rectal cancer
goal → Prove that immunotherapy alone can eliminate rectal tumors without removing the organ
Andrea Cercek
A medical oncologist at Memorial Sloan Kettering and lead researcher for the AZUR-1 trial
goal → Confirm that patients can safely avoid surgery, radiation and chemotherapy without raising the risk of cancer returning
Colorectal Cancer Alliance
A US patient advocacy group supporting individuals affected by bowel cancers
goal → Ensure patients receive early tumor testing so they know whether non-surgical options exist
AnaptysBio
The biotechnology firm that discovered the drug and collects royalties under a licensing agreement
goal → Maintain its financial returns as the medicine gains regulatory clearance for wider use
Adults with MSI-H/dMMR locally advanced rectal cancer
Patients whose tumors contain DNA-repair flaws that make them unusually vulnerable to immunotherapy
goal → Clear the cancer while keeping their organs intact and avoiding disabling surgeries
In short
Some patients with locally advanced rectal cancer can now receive an immunotherapy drug that may allow them to bypass chemotherapy, radiation and invasive surgery. The clear next step is a widespread push to test newly diagnosed patients for specific DNA-repair flaws so eligible individuals can attempt organ-preserving care. Whether this becomes the permanent standard remains uncertain because researchers still need several years of monitoring to confirm that tumors do not return.
On October 19, 2026, the United States Food and Drug Administration granted accelerated approval to dostarlimab, sold as Jemperli by GSK. The treatment trains the immune system to recognize and destroy cancer cells. It applies only to adults with stage II or III rectal cancer whose tumors carry specific genetic repair defects known as MSI-H or dMMR, which leave cells heavily mutated and easier for body defenses to spot.
Standard care often requires removing part or all of the rectum, which can leave patients with a colostomy bag and lifelong changes to digestion, urination and sexual health. Dostarlimab offers a way to avoid those life-altering operations if the tumor vanishes entirely. In the AZUR-1 clinical trial, 71% of patients required no further treatment and remained free of cancer progression at the interim check. Independent reviewers found that 47% achieved a complete disappearance of cancer that lasted at least one year.
Flagged by: Life & Health Science Barometer · 24 October 2026
Previously in this story
GSK wins Japan approval for hepatitis cure
2 September 2026British drugmaker also secures fast-track US review for its rectal cancer therapy
How it unfolded
Commercial momentum builds ahead of medical conference
Financial disclosures highlighted rising drug sales and legal disputes, while researchers prepared to present detailed trial evidence to European cancer specialists. The approaching scientific meeting signaled that mature clinical findings were ready for formal peer review.
US regulator authorizes non-surgical cancer therapy
Federal regulators cleared dostarlimab for adults with locally advanced rectal tumors marked by specific DNA-repair defects, four months earlier than planned. The decision gives qualifying patients immediate access to a medical option that could remove the need for standard surgery.
Fast-track clearance establishes a new standard
The regulatory decision formally introduced dostarlimab as an upfront, standalone treatment that blocks the PD-1 protein, a molecular shield tumors use to evade immune attacks. Health officials in Canada, Britain, Switzerland and Israel continue to review the evidence independently.
Early success meets the requirement for lasting proof
Data submitted to the government showed that most trial participants avoided subsequent treatments, but independent reviewers verified fewer sustained responses than the clinic doctors had reported. To ensure the early benefits represent genuine long-term control, regulators mandated continued monitoring until 2030.
Where things stand
The regulatory decision is in effect across the United States for qualifying patients whose tumors show confirmed genetic repair defects, estimated at 3% to 10% of cases. Patients whose tumors clear completely will undergo regular scans and internal examinations every four to six months to detect any early signs of return.
The central medical question is whether these early tumor clearances hold up over three to five years without placing patient survival at risk compared to standard surgery. Regulators will re-evaluate the treatment as final survival data arrive through July 2030, while health authorities in Europe and other regions finish their own independent reviews.